/

JUNS

Jupiter Neurosciences, Inc.Pre-market

3.36+0.32 +10.53%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayPre-market 3.46 +2.98%

Open

3.00

Prev close

3.04

Day range

3.003.50

52-week range

2.25135.75

Volume

70.77K0.07×

Mkt cap

4.43M

P/E ttm

—

Fwd P/E

56.00

EPS ttm

-18.94

Div yield

0.00%

Earnings

—

From 52w high

−97.52%

Price Chart

Yahoo Finance · delayed

JUNSOct 13, 2026O 3.00H 3.50L 3.00C 3.36+0.32 (+10.53%)Vol 71.30K

SMA 503.86
SMA 20025.39

1Y change −96.91% since Oct 13, 2025 close466 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

JUNS Jupiter Neurosciences, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +17.48%
1 month: +10.16%
3 months: −74.83%
6 months: −88.63%
Year to date: −95.61%
1 year: −96.91%

Valuation & ownership

Market cap: 4.43M
Enterprise value: 2.81M
P/E (ttm): —
Forward P/E: 56.00
PEG ratio: —
Price / book: —
Price / sales (ttm): 68.48
EV / EBITDA: —
EPS (ttm): -18.94
EPS (forward): 0.0600
Beta (5y monthly): —
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 1.32M
Float: 564.08K
Short % of float: 3.12%
Short ratio (days): 0.55
Held by insiders: 29.96%
Held by institutions: 2.25%
Avg volume (3m): 984.45K
50-day average: 3.86
200-day average: 25.39
52-week change: −96.91%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 51.7
vs 50-day SMA: −12.96%
vs 200-day SMA: −86.77%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 12.44%
Realised vol (20d, ann.): 94.1%
From 52-week high: −97.52%
From 52-week low: +49.27%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 64.69K
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 0.00%
Operating margin: -11313.45%
Profit margin: 0.00%

DES

About Jupiter Neurosciences, Inc.

Yahoo Finance profile

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer's disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clinical trial for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. It is also involved in the commercialization and sale of GLO for skin beauty, MND for mental clarity, and PWR for energy, endurance, and muscle recovery under the Nugevia brand name. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.

Sector: Healthcare
Industry: Biotechnology
Employees: 5
Headquarters: Jupiter, FL, United States
Website: jupiterneurosciences.com
Officers: Mr. Christer Rosen Co-Founder, CEO & Chairman of the Board
Ms. Alison D. Silva MA, MS

SEAS

Seasonality · JUNS

2024–2026 · monthly returns

Strongest month Jul +37.25%Weakest month Jan −90.37%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-48.2	0.4	-29.1	0.8	-32.5	-16.4	-57.9	-47.6	-31.1	37.7			−95.6%
2025	-90.4	-36.8	-6.3	6.2	19.6	31.6	37.3	5.0	19.7	-18.8	-14.3	-16.7	−90.5%
2024													—

INSD

Insider Activity · JUNS

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Mar 1, 2026	Hayward Marshall A Ph.D.Officer and Director	Conversion of Exercise of derivative security at price 0.01 per share.	1.01M	$2.25K
Jun 30, 2025	Rosen ChristerChief Executive Officer	Purchase at price 1.01 - 1.02 per share.	3.6K	$3.67K
Jun 30, 2025	Silva Alison DPresident	Purchase at price 1.03 per share.	750	$772
Jun 29, 2025	Rosen ChristerChief Executive Officer	Purchase at price 0.98 - 1.06 per share.	7.8K	$7.99K
Jun 29, 2025	Silva Alison DPresident	Purchase at price 1.00 - 1.05 per share.	1.8K	$1.85K
Jun 1, 2025	Weis HolgerDirector	—	85.8K	—
Jun 1, 2025	Kampf Julie B.Director	—	82.9K	—
Jun 1, 2025	Elmasri Saleem CChief Financial Officer	—	66.3K	—
Jun 1, 2025	Hemmerly Nicholas HDirector	—	95.5K	—
Jun 1, 2025	Rosen ChristerChief Executive Officer	—	973.5K	—
Jun 1, 2025	Rosen Alexander Gustaf ErikOfficer	—	261.2K	—
Jun 1, 2025	Silva Alison DPresident	—	110.2K	—
Jan 21, 2025	Weis HolgerDirector	Conversion of Exercise of derivative security at price 2.80 per share.	10.8K	$30.19K
Jan 21, 2025	Brady Allison WDirector	Conversion of Exercise of derivative security at price 2.80 per share.	21.8K	$60.90K

JUNS

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

JUNS

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Jupiter Neurosciences, Inc.

Seasonality · JUNS

Insider Activity · JUNS

Congress Trades · JUNS

Investors Holding JUNS

Investors Holding JUNS

Congress Trades · JUNS

Seasonality · JUNS

Insider Activity · JUNS

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Jupiter Neurosciences, Inc.

Earnings & Dividends

News